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Abstract: Cytomegalovirus (CMV) retinitis remains the most common opportunistic ocular 
infection in immunocompromised patients. Patients with immunocompromising diseases, such 
as acquired immunodeficiency syndrome, inherited immunodeficiency states, malignancies, 
and those on systemic immunosuppressive therapy, are known to be at risk. Recently, it has 
been suggested that patients undergoing intravitreal injection of immunosuppressive agents 
may also be predisposed. One previous case report speculated that there may be an additional 
risk for CMV retinitis in acquired immunodeficiency syndrome patients with venoocclusive 
disease. This case study presents a case of CMV retinitis following central retinal vein occlusion 
in a patient on systemic immunosuppressants.
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Case presentation
An 82-year-old Caucasian male presented to a community ophthalmologist with 
6 months of decreased vision in the left eye. Initial workup revealed abnormal fundus 
findings and the patient was referred to a local retina specialist who diagnosed nonis-
chemic central retinal vein occlusion (CRVO) of the left eye, demonstrated by fluo-
rescein angiography. At that time, visual acuity in the affected eye was 20/30. Several 
weeks later, the patient was seen in follow-up and, on fundus exam of the affected 
eye, was noted to have new, apparently unrelated changes. He was subsequently 
referred to the Havener Eye Institute in July 2011 for further evaluation, with concern 
for a viral retinitis.
The patient’s past medical history was significant, as he had had a kidney trans-
plant in 2007 following advanced diabetic nephropathy. His immunosuppressive 
regimen at the time of presentation consisted of tacrolimus 5 mg twice daily, myco-
phenolate mofetil 750 mg twice daily, and prednisone 5 mg daily. His cytomegalovirus 
(CMV) status at the time of transplant was donor and recipient positive, and he had 
no history of systemic CMV infection. Prior to the clinic’s evaluation, his most 
recent laboratory tests revealed a normal white blood cell count and a normal 
  tacrolimus level.
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Figure 1 Color fundus photos showing: (A) Dilation, tortuousity, and sheathing 
along  the  superior  venous  arcade,  with  scattered  flame-shaped  and  intraretinal 
hemorrhages; (b) 5 disc diameter white, granular-appearing lesion with intralesional 
hemorrhage in the superior periphery; (C) Composite image of the same eye.
sheathing of the superior arcades and, in the superior 
periphery, a 5-disc diameter area of granular whitening with 
intralesional hemorrhage consistent with CMV retinitis 
(Figure 1).
The patient was started on valganciclovir 900 mg twice 
daily for 2 weeks, which was then decreased to 450 mg daily. 
At one month, the left eye vision improved to 20/25, with 
regression of the retinal lesion.
Discussion
The hematogenous dissemination of CMV is carried out by 
polymorphonuclear leukocytes and monocytes.1 Endocytosis 
of infected leukocytes by retinal vascular endothelial cells, 
with subsequent intracellular replication, endothelial cell 
damage, and ultimate compromise of the blood-retina barrier 
is thought to be the primary pathogenic mechanism by which 
CMV invades the neuroretina.2 However, some autopsy 
studies of acquired immunodeficiency syndrome (AIDS)-
infected patients with CMV retinitis have failed to demon-
strate CMV infection within the retinal vascular endothelial 
cells, suggesting the possibility of an alternative pathogenic 
pathway in some patients.3,4
It has been suggested that the vascular breaches and leak-
age from microaneurysms frequently seen in patients with 
AIDS may facilitate the passage of infected leukocytes 
through the blood retinal barrier, without infection of 
endothelial cells.5,6 Mansour et al reported a case of hemi-
retinal vein occlusion in a patient with AIDS who subse-
quently developed CMV retinitis in the same neuroretinal 
distribution.7 The authors speculated that the facilitated pas-
sage of infected leukocytes across the blood-retinal barrier 
in AIDS patients might be further enhanced by the venous 
stasis and ischemic endothelial damage caused by venooc-
clusive disease.7
A review of the literature yielded two other cases of venooc-
clusive events followed by CMV retinitis – both in locally 
immunocompromised patients. Park and Byeon reported a 
77-year-old woman without any known immunocompromising 
disease state and who was not taking systemic immunosup-
pressive medications, who was diagnosed with CMV retinitis 
four months after intravitreal triamcinalone injection for CRVO-
related macular edema.8 Similarly, Vertes et al reported an 
immunocompetent 78-year-old woman who underwent intra-
vitreal triamcinalone injection for a branch retinal vein occlu-
sion, then 3 months later, presented with CMV retinitis in the 
same hemispheric distribution.9 These reports emphasized 
the potential of local intravitreal immunosuppression to pre-
dispose to CMV retinitis – an occurrence which has been   
Examination revealed 20/40 vision in the left eye with no 
afferent papillary defect and normal intraocular pressure. 
There was 3+ nuclear sclerotic cataract and mild vitritis. 
Fundus examination showed a normal optic disc with scattered 
intraretinal hemorrhage in the macula, tortuousity, and 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
602
Welling et alClinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2012:6
reported elsewhere.8–13 Neither mentioned CRVO-related 
vasculopathy as a possible contributing factor.
The association of CMV retinitis with systemic immuno-
suppression following solid organ transplantation is well 
documented.14–16 This study’s patient was on systemic immu-
nosuppresants for 4 years without complication, then, within 
2 months of developing CRVO, developed CMV retinitis in 
the same eye. While these events could have occurred inde-
pendently and their sequence may have been coincidental, the 
authors suggest that the events may support the assertion 
made by Mansour et al,7 that secondary venous stasis and 
endothelial damage after venooculsive events may facilitate 
the development of CMV retinitis in patients already at risk.
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